Advanced in Hepatitis D

Chao-wei W. Hsu

Chang Gung Memorial Hospital Linkou Branch
Taoyuan, TNQ, TW 
Advanced in Hepatitis D
Chang Gung Memorial Hospital Linkou Branch
Taoyuan, TNQ, TW 
OverviewLocationsClinical Research

Overview

Chao-wei Hsu practices in Taoyuan, Taiwan. Hsu is rated as an Advanced expert by MediFind in the treatment of Hepatitis D. Their top areas of expertise are Hepatitis B, Hepatitis, Hepatitis D, and Liver Cancer.

Their clinical research consists of co-authoring 78 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Hepatitis D.

Locations

Chang Gung Memorial Hospital Linkou Branch
Taoyuan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Enrollment Status: Terminated
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

78 Total Publications

Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study.
Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study.
Journal: Annals of medicine
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsu's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile